Triazolo-azepine Bicyclic Modulators for Selective Aβ42 Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and related conditions, such as cerebral amyloid angiopathy and Down syndrome, are inadequate in effectively reducing the deposition of neurotoxic amyloid beta peptides, particularly Aβ42, which contribute to disease progression.
Innovation Solution
Development of compounds that modulate γ-secretase activity to selectively reduce Aβ42 production, promoting the formation of shorter, less neurotoxic Aβ isoforms like Aβ38, by targeting the γ-secretase complex with specific bicyclic compounds and their pharmaceutically active salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If γ-secretase is inhibited to reduce Aβ production, then amyloid plaque formation is reduced, but shorter Aβ isoforms (Aβ38, Aβ37) which are less neurotoxic are not selectively promoted
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target specific regions or conformational states within the γ-secretase complex to achieve preferential reduction of Aβ42 over other isoforms. The bicyclic compounds (I) and (II) are structurally optimized to interact with specific pockets or interfaces in the γ-secretase complex that are associated with Aβ42 generation, thereby achieving localized modulation of isoform production rather than uniform inhibition of all Aβ peptides.
Solution Approach 2:
The patent employs parameter changes by modifying physical or chemical parameters of the γ-secretase complex through compound binding, such as altering the conformational state, flexibility, or catalytic efficiency of specific subunits (presenilin, nicastrin, APH-1, PEN-2). These parameter changes result in a shift in the enzymatic cleavage pattern, preferentially reducing Aβ42 production while maintaining or enhancing production of shorter, less neurotoxic isoforms like Aβ38 and Aβ37.
2Object-affected harmful factors
If selective Aβ42 reduction is achieved through γ-secretase modulation, then neurotoxicity is reduced, but complete inhibition of γ-secretase activity is avoided
Solution Approach 1:
The patent applies partial action by designing compounds that achieve sufficient modulation of γ-secretase activity to reduce Aβ42 neurotoxicity without completely inhibiting the enzyme complex. The bicyclic compounds (I) and (II) are optimized to produce a partial effect that shifts the isoform distribution toward shorter, less neurotoxic peptides while maintaining overall γ-secretase function for essential substrates like Notch receptors, thereby avoiding the harmful effects of complete inhibition.
Solution Approach 2:
The patent converts the potential harm of γ-secretase inhibition (which could disrupt essential physiological functions) into a benefit by selectively modulating the enzyme to reduce pathogenic Aβ42 while preserving necessary Aβ isoforms and Notch signaling. The compounds transform the dual-natured γ-secretase activity from a harmful source of neurotoxic peptides into a beneficial tool for selective Aβ42 reduction, maintaining homeostasis of other substrates.
3Object-affected harmful factors
If bicyclic compounds are designed to target γ-secretase, then Aβ42 secretion is inhibited, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the γ-secretase complex into functional subunits (presenilin, nicastrin, APH-1, PEN-2) and designing bicyclic compounds that target specific regions or interfaces within this segmented structure. The compounds (I) and (II) contain distinct structural modules (bicyclic core, substituent groups R1-R6) that can independently interact with different parts of the γ-secretase complex, allowing for optimized binding to Aβ42-associated regions while maintaining overall structural efficiency.
Solution Approach 2:
The patent employs composite material principles by creating bicyclic compounds that combine multiple structural elements (two fused rings, various substituent groups, stereocenters) into a single molecular entity. This composite structure allows the compound to simultaneously engage multiple interaction points on the γ-secretase complex, achieving potent and selective Aβ42 reduction through multi-valent binding rather than relying on a single interaction site.
Data Source
AI summary
The present invention relates to compounds of formula (I), wherein R is hydrogen or halogen, wherein R may be different if n = 2 or 3; n is 1, 2 or 3; (II) is a disubstitued bicyclo[1,1,1]pentane or bicyclo[2,2,2]octane as defined below : (III) or (IV); or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.